Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
absent, accredited, agent, ATM, benchmark, billion, Cannon, cemiplimab, cleared, codified, daily, Deniger, Drew, EGFR, endometrial, Hagen, Heidi, hotspot, India, intravenously, investor, Istari, joined, Karyopharm, leadership, library, low, mutated, Novocure, Optune, ovarian, PACT, primary, role, Sath, Satyavrat, Shukla, sixty, Sleeping, sublicensee, thesix, timeframe, underlying
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view